Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | XPO1 | O14980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070093 | 0.92 | CPT1A (0.40) | CPT1AKITP2RY12KDM5ATLR9 | |
| SCHEMBL10069537 | 0.90 | HSD11B1 (0.43) | CPT1AKITP2RY12HSD11B1KDM5A | |
| SCHEMBL1653319 | 0.89 | KIT (0.46) | KITP2RY12KDM5ATLR9TLR8 | |
| SCHEMBL10070100 | 0.89 | CPT2 (0.49) | CPT1AKITP2RY12 | |
| SCHEMBL10069541 | 0.86 | AKT1 (0.39) | CPT1AKITAKT1AKT2KDM5A | |
| SCHEMBL10070551 | 0.86 | AOC3 (0.45) | CPT1AKITAKT1AKT2KDM5A | |
| SCHEMBL10069718 | 0.85 | CPT1A (0.45) | CPT1AKITP2RY12AKT1AKT2 | |
| SCHEMBL10070536 | 0.84 | CPT1A (0.46) | CPT1AKITP2RY12AKT1AKT2 | |
| SCHEMBL10069716 | 0.84 | HTR2B (0.42) | P2RY12HSD11B1KDM5ATLR9TLR8 | |
| SCHEMBL10070119 | 0.83 | LIPE (0.47) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | CPT1A 1233/4885KIT 681/4885P2RY12 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.